15 completed, 8 terminated, 1 active not recruiting, 1 recruiting. 26 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 15, Terminated 8, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 3, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow Refractory Hairy Cell Leukemia: new trials by email Literature Review of Refractory Hairy Cell Leukemia trials Research Report on Refractory Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 30 | 2013-10-08 | 2026-06-25 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma bevacizumab, cediranib maleate - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 57 | 2007-05-01 | 2014-02-19 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma oxaliplatin, etoposide - Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2004-11-01 | 2014-02-24 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Hairy Cell (26) · Burkitt Lymphoma (23) · Leukemia, Lymphocytic, Chronic, B-Cell (23) · Lymphoma, B-Cell, Marginal Zone (22) · Lymphoma, Follicular (22) · Lymphoma, Mantle-Cell (22) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (22) · Waldenstrom Macroglobulinemia (21) · Intraocular Lymphoma (20) · Lymphoma, Large B-Cell, Diffuse (20) · Lymphoma, Large-Cell, Immunoblastic (18) · Lymphoma, Non-Hodgkin (18) · Mycosis Fungoides (18) · Sezary Syndrome (18) · Lymphoma, Large-Cell, Anaplastic (17)
Hematologic Diseases (26) · Hemic and Lymphatic Diseases (26) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Leukemia (26) · Lymphatic Diseases (26) · Lymphoproliferative Disorders (26) · Neoplasms (26) · Neoplasms by Histologic Type (26) · Disease Attributes (25) · Leukemia, Lymphoid (25) · Lymphoma (25) · Pathologic Processes (25) · Pathological Conditions, Signs and Symptoms (25) · Chronic Disease (24)
Rituximab (6) · Lenalidomide (3) · Peripheral Blood Stem Cell Transplantation (3) · fludarabine phosphate (3) · Bendamustine Hydrochloride (2) · CTLA-4 Antigen (2) · Cyclosporine (2) · Ipilimumab (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · Acetaminophen (1) · Azacitidine (1) · Bevacizumab (1) · Biopsy (1) · Brentuximab Vedotin (1)
National Cancer Institute (NCI) (14) · City of Hope Medical Center (3) · Fred Hutchinson Cancer Center (3) · Joseph Tuscano (1) · Mayo Clinic (1) · Morphotek (1) · Northwestern University (1) · Stanford University (1) · Wake Forest University Health Sciences (1)
United States (25) · Canada (2) · Italy (2) · Germany (1)
Adam Petrich, MD (1) · Ajay Gopal (1) · Brenda Sandmaier (1) · David Hong (1) · David Maloney (1) · Elizabeth Budde (1) · George A. Fisher, MD, PhD (1) · Grzegorz Nowakowski (1) · Ibrahim T Aldoss (1) · John Byrd (1) · John Deeken (1) · John Gerecitano (1) · John Sarantopoulos (1) · Joseph M Tuscano (1) · Leslie Andritsos (1)
PMID 32499241, PMID 22259028, PMID 23393050, PMID 24474568, PMID 26853648, PMID 27118452, PMID 28314788, PMID 29292843, PMID 30562587, PMID 31617432, PMID 34515338, PMID 35622074
P30CA015704 (3), U01CA097452 (3), P30CA015083 (2), P30CA033572 (2), U01CA062505 (2), U01CA076576 (2), U01CA121947 (2), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA008748 (1), P30CA012197 (1), P30CA016058 (1), P30CA016672 (1), P30CA021765 (1)